Jason Luke

Jason Luke is a medical oncologist and translational researcher focused on innate immune activation as a strategy to sensitize immunologically cold tumors to checkpoint inhibitor therapy. He has led clinical trials of STING agonists, innate immune modulators, and anti-TIGIT combinations, and is one of the most active investigators in the field of novel IO combination strategies beyond anti-PD-1/CTLA-4. His laboratory studies mechanisms of primary and acquired immunotherapy resistance and the role of the cGAS-STING pathway in linking DNA damage responses to anti-tumor immunity.